麥卡遜 (MCK) 2027 Q2 法說會逐字稿

內容摘要

  1. 摘要
    • Q2 營收年增 8%,調整後 EPS 年增 18%,各事業群皆有成長,營運動能持續。
    • 上修 2027 財年調整後 EPS 指引至 $45.60-$46.40(原為 $44.20-$45),反映上半年強勁表現與展望信心。
    • Precision Medicine Group 併購案已完成,Option Care Health 投資案進行中,市場反應正面,強化長期成長動能。
  2. 成長動能 & 風險
    • 成長動能:
      • 北美藥品分銷業務持續受惠於處方量成長、GLP-1 及專科藥品需求提升。
      • Oncology & Multispecialty 平台受惠於新療法上市、專科分銷與 GPO 服務需求強勁。
      • Prescription Technology Solutions 受惠於存取與可負擔性解決方案需求,GLP-1 及其他治療領域帶動成長。
      • Precision Medicine Group 併購案擴大臨床試驗、罕見疾病與細胞基因治療服務,強化腫瘤及生技服務平台。
      • Option Care Health 投資案切入居家及社區輸注市場,布局未來專科照護趨勢。
    • 風險:
      • 品牌藥價格下調及品牌轉學名藥趨勢,對營收成長有壓抑作用。
      • 340B 政策變動及美國醫療政策環境不確定性,可能影響部分業務量與客戶行為。
      • MedSurg 事業群產品組合變化及季節性流感疫情,造成獲利波動。
  3. 核心 KPI / 事業群
    • 總營收:年增 8% 至 $1110 億,四大事業群皆有成長。
    • 調整後 EPS:年增 18% 至 $11.68,若排除一次性項目,年增 24%。
    • 北美藥品分銷營收:年增 6% 至 $914 億,GLP-1 藥品分銷營收 $160 億,年增 26%,季增 8%。
    • 北美藥品分銷營業利益:年增 22% 至 $10 億,主因專科分銷與策略客戶帶動。
    • Oncology & Multispecialty 營收:年增 24% 至 $150 億,營業利益年增 8%(排除一次性利益年增 23%)。
    • Prescription Technology Solutions 營收:年增 10% 至 $15 億,營業利益年增 18%。
    • MedSurg 營收:年增 5% 至 $31 億,營業利益年減 10%。
    • 自由現金流:$29 億,資本支出 $1.23 億。
  4. 財務預測
    • 2027 財年營收成長預估 6%-10%。
    • 2027 財年營業利益成長預估 12%-16%。
    • 2027 財年自由現金流預估 $45 億-$49 億,資本支出維持穩健。
  5. 法人 Q&A
    • Q: Precision Medicine Group 與 Option Care Health 併購/投資案如何影響報表分部與毛利結構?
      A: Precision Medicine Group 併入 Oncology & Multispecialty 事業群,屬高毛利業務,預計 2027 財年貢獻 EPS $0.10-$0.20,三年內累積 EPS 貢獻 $1.60-$1.80。Option Care Health 為少數股權投資,採權益法列報於 Corporate segment,不影響事業群毛利結構。
    • Q: Option Care Health 投資案與腫瘤業務有何策略連結?
      A: 公司具備腫瘤、罕見疾病、細胞基因治療等專科能力,Option Care Health 可補足居家及社區輸注通路,強化未來專科照護布局,與現有資產高度互補。
    • Q: 北美藥品分銷業務成長動能是否具持續性?未來展望如何?
      A: Q2 成長動能來自處方量、專科藥品、GLP-1 等多元來源,營運槓桿顯著。下半年預期動能延續,受惠於市場趨勢、客戶續約(如 CVS 合約延長至 2032 年)及自動化投資,對長期成長具信心。
    • Q: 340B 政策變動及美國醫療政策環境對業務有何影響?
      A: 公司在 340B 各通路皆有布局,政策變動將密切追蹤並協助客戶調整,預期不會對公司造成重大財務影響。整體醫療政策環境仍具不確定性,公司將持續與政策制定者合作,維護社區醫療可近性與品質。
    • Q: Precision Medicine Group 與 Option Care Health 整合難度與過往 M&A 有何不同?
      A: Precision Medicine Group 與現有業務高度互補,整合重點在於資源互補與服務擴充,非大規模整併。Option Care Health 為少數股權投資,由 CD&R 主導營運,McKesson 提供專科與供應鏈專業,屬於策略性布局。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to McKesson's second quarter fiscal 2027 earnings conference call. Please be advised that today's conference is being recorded.

    歡迎參加麥克森(McKesson)2027 會計年度第二季財報電話會議。請注意,今天的會議將被錄音。

  • At this time, I would like to turn the call over to Paula Adkison, SVP of Corporate Finance and Investor Relations. Please go ahead.

    此刻,我想把電話交給企業財務與投資人關係資深副總裁 Paula Adkison。請開始。

  • Paula Adkison - Senior VP of Corporate Finance, Investor Relations & Strategic

    Paula Adkison - Senior VP of Corporate Finance, Investor Relations & Strategic

  • Thank you, operator. Good afternoon, and welcome, everyone, to McKesson's second quarter fiscal 2027 earnings call. Today, I'm joined by Brian Tyler, our Chair and Chief Executive Officer; and Kenny Cheung, our Chief Financial Officer. Brian will lead off, followed by Kenny, and then we will move to a question-and-answer session.

    謝謝,接線員。各位下午好,歡迎大家參加麥克森 2027 會計年度第二季財報電話會議。今天與我一同出席的有董事長兼執行長 Brian Tyler,以及財務長 Kenny Cheung。Brian 將先發言,接著由 Kenny,然後我們將進入問答環節。

  • Today's discussion will include forward-looking statements such as forecasts about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements.

    今天的討論將包含前瞻性陳述,例如對麥克森營運與未來業績的預測。請參閱今日財報新聞稿與簡報投影片中的警示性聲明(可於 investor.mckesson.com 取得),並參考我們最近一期年度及定期向美國證券交易委員會(SEC)申報文件中的「風險因素」章節,以取得可能導致實際結果與前瞻性陳述存在重大差異之風險因素的更多資訊。

  • Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and guidance assumptions.

    關於我們在本次網路直播中將討論的非 GAAP 財務衡量指標資訊(包括與 GAAP 結果的調節表),可在今日的財報新聞稿與簡報投影片中找到。簡報投影片亦包含本季業績摘要與財測假設。

  • With that, let me turn it over to Brian.

    接下來,我把時間交給 Brian。

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Good afternoon, everyone. Thank you for joining our call. Today, we reported another strong quarter, reflecting continued momentum across our business and disciplined execution against our strategic priorities. Second quarter revenues increased 8% with growth across all segments, while adjusted earnings per diluted share increased 18% year-over-year. These results demonstrate the strength and resilience of McKesson's operating model, the momentum across our diversified health care platform and our continued focus on delivering sustainable long-term value for our customers and partners, and importantly, for our shareholders.

    各位下午好。感謝各位參加本次電話會議。今天我們公布了另一個強勁季度,反映我們各項業務持續的動能,以及針對策略優先事項的紀律性執行。第二季營收成長 8%,各事業部門皆有成長;同時,調整後稀釋每股盈餘較去年同期成長 18%。這些結果展現了麥克森營運模式的強健與韌性、我們多元化醫療保健平台的動能,以及我們持續專注於為客戶與合作夥伴,並且更重要的是為股東,創造可持續的長期價值。

  • As a result of our strong performance and our confidence in the outlook for our business, we are raising our fiscal 2027 adjusted earnings per diluted share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45. Our results continue to demonstrate the benefits of our strategic focus, differentiated capabilities and disciplined capital deployment. Across the enterprise, we remain focused on advancing our mission of improving health outcomes for all while executing against the strategic priorities that we believe will drive long-term sustainable growth.

    基於我們強勁的表現以及對業務前景的信心,我們將 2027 會計年度調整後稀釋每股盈餘指引自先前的 44.20 至 45.00 美元,上調至 45.60 至 46.40 美元。我們的業績持續展現策略聚焦、差異化能力與紀律性資本配置所帶來的效益。在整個企業層面,我們仍專注於推進「改善所有人的健康結果」這一使命,同時執行我們相信將驅動長期可持續成長的策略優先事項。

  • Now let's discuss how we're translating these priorities into actions across the enterprise. I'll start with our people and culture, which remain foundational to everything we do. We continue to invest in experiences and programs that strengthen our culture and support engagement, development and well-being.

    現在讓我們談談如何在整個企業中把這些優先事項轉化為具體行動。我將先從我們的人才與文化談起,這仍是我們一切工作的基礎。我們持續投資於各種體驗與計畫,以強化文化並支持員工的投入度、發展與身心福祉。

  • Recently, we launched Family Forward, a new employee resource group that fosters connection and supports employees with caregiving responsibilities at every stage of life. We now have 12 employee-led resource groups across the company, and I am proud of how these groups enrich our culture and advance inclusion for all members of Team McKesson.

    近期,我們推出了 Family Forward,這是一個新的員工資源團體,旨在促進連結,並在生命各階段支持肩負照護責任的員工。目前公司已有 12 個由員工主導的資源團體;我為這些團體如何豐富我們的文化並推動 Team McKesson 所有成員的共融而感到自豪。

  • Our annual impact report published in July highlights additional examples of the progress we're making to advance health outcomes by supporting our communities, developing our people and enabling our partners to improve care for patients. Building on a strong commitment to our mission and purpose, we continue to accelerate our enterprise strategy with a focus on strengthening our North American distribution business and advancing our growth platforms in oncology, multi-specialty and biopharma services.

    我們於 7 月發布的年度影響力報告,亦列舉更多我們在支持社區、培育人才,以及協助合作夥伴改善病患照護以推進健康結果方面所取得進展的例子。在對使命與宗旨的堅定承諾之上,我們持續加速企業策略,聚焦於強化北美配送業務,並推進我們在腫瘤、多專科與生物製藥服務等成長平台。

  • During the quarter, we were pleased to announce a strategic transaction that directly supports these priorities, our acquisition of Precision Medicine Group, which we closed this week. We're pleased to welcome PMG to McKesson as we advance our shared commitment to accelerating innovation and improving patient access to care.

    本季期間,我們很高興宣布一項直接支持這些優先事項的策略性交易:收購 Precision Medicine Group,我們已於本週完成交割。在推進共同承諾、加速創新並改善病患取得照護的可近性之際,我們很高興歡迎 PMG 加入麥克森。

  • Expanding access to clinical trials is an important element of our oncology strategy, connecting innovation in drug development with community-based practices where patients receive care. In 2022, we established our joint venture with Sarah Cannon Research Institute, bringing together the US Oncology Network's provider reach and practice management expertise with SCRI's research infrastructure and clinical trial expertise to support these practices. Precision Medicine Group builds on this foundation, adding complementary clinical research expertise in oncology, rare and orphan diseases, and cell and gene therapies. Its global footprint and experience conducting late-stage clinical trials broaden our ability to support clinical development and expand patient access to innovative therapies.

    擴大臨床試驗的可近性是我們腫瘤策略的重要一環,能將藥物研發創新與病患接受照護的社區型醫療機構連結起來。2022 年,我們與 Sarah Cannon Research Institute 成立合資企業,結合 US Oncology Network 的醫療提供者覆蓋範圍與診所管理專長,以及 SCRI 的研究基礎設施與臨床試驗專業,以支持這些機構。Precision Medicine Group 在此基礎上再向前延伸,增添在腫瘤、罕見與孤兒疾病,以及細胞與基因療法方面互補的臨床研究專長。其全球布局與執行後期臨床試驗的經驗,擴大了我們支持臨床開發並提升病患取得創新療法可近性的能力。

  • The acquisition also advances our biopharma services strategy. Precision Medicine Group's market access and commercialization services complement our existing access and affordability solutions, broadening the support we can provide to biopharma partners as they bring their therapies to market.

    此次收購也推進了我們的生物製藥服務策略。Precision Medicine Group 的市場准入與商業化服務,與我們既有的可近性與可負擔性解決方案相互補強,擴大我們在合作夥伴將療法推向市場時所能提供的支援範圍。

  • In addition, last month, we signed a definitive agreement to make a strategic investment in Option Care Health, the nation's largest independent provider of home and alternate site infusion services. As specialty therapies grow in importance and complexity, this transaction reflects our conviction that care will increasingly be delivered in lower-cost community settings at or closer to home. McKesson knows this shift well. For over 25 years, we have supported the US Oncology Network and over 3,400 providers in delivering connected high-quality care in the community.

    此外,上個月我們簽署了最終協議,將對 Option Care Health 進行策略性投資;該公司是全美最大的獨立居家與替代照護場域輸注服務提供者。隨著專科療法的重要性與複雜度日益提升,這筆交易反映我們的信念:照護將愈來愈多在成本較低的社區場域、在家中或更接近家中的地方提供。麥克森對這一轉變並不陌生。25 年以上以來,我們一直支持 US Oncology Network 以及超過 3,400 位醫療提供者,在社區中提供連結式的高品質照護。

  • Option Care Health's clinical model and national infusion footprint across home and ambulatory sites are well aligned with these priorities. As a strategic investor, we look forward to bringing our specialty expertise to help broaden access to complex therapies and to support its continued growth. And we're pleased to partner with CD&R, which brings a strong track record of supporting companies and creating long-term value. CD&R will own a majority interest in Option Care Health at closing. The transaction is subject to customary closing conditions, including approval by Option Care Health stockholders and the receipt of required regulatory approvals.

    Option Care Health 的臨床模式,以及其涵蓋居家與門診場域的全國輸注服務布局,與這些優先事項高度一致。作為策略性投資人,我們期待運用我們在專科領域的專業,協助擴大複雜療法的可近性並支持其持續成長。我們也很高興與 CD&R 合作;CD&R 在支持企業並創造長期價值方面擁有優異的實績。交易完成交割時,CD&R 將持有 Option Care Health 的控股權益。本交易仍須符合慣常交割條件,包括取得 Option Care Health 股東核准以及取得所需的監管核准。

  • In our Oncology & Multispecialty platform, we are encouraged by strong market trends, supported by drug innovation and stable utilization. As new therapies come to market, our deep expertise in specialty distribution and specialty pharmacy, together with our strong connections across community-based care, position us well to enable access to these medications.

    在我們的「腫瘤與多專科」平台方面,我們對強勁的市場趨勢感到鼓舞,這些趨勢受到藥物創新與穩定使用量的支持。隨著新療法上市,我們在專科配送與專科藥局方面的深厚專業,加上我們與社區型照護體系的緊密連結,使我們具備良好條件來促進這些藥物的可近性。

  • Within the oncology platform, we continue to reinforce our value to community-based providers by bringing together complementary capabilities, which include community-based practice management experience, clinical research expertise and data-enabled capabilities. As we welcome Precision Medicine Group, we're excited to build on this foundation and accelerate our strategy.

    在腫瘤平台內,我們持續整合互補能力,以強化我們對社區型醫療提供者的價值;這些能力包括社區型診所管理經驗、臨床研究專業,以及以數據驅動的能力。在歡迎 Precision Medicine Group 加入之際,我們很期待在此基礎上再接再厲,加速推進我們的策略。

  • Within our retina and ophthalmology platform, we welcome Spectrum Vision Partners and its over 150 providers to the PRISM Vision Group, further expanding its footprint. This is another meaningful addition to our platform. We're encouraged by its continued strong performance, which demonstrates its compelling value proposition to providers and their patients. Across oncology and other specialty areas, our distribution capabilities, data-enabled insights, clinical expertise and experienced supporting providers allow us to create value for customers and improve patient access to care.

    在我們的視網膜與眼科平台方面,我們歡迎 Spectrum Vision Partners 及其超過 150 位醫療提供者加入 PRISM Vision Group,進一步擴大其布局。這是我們平台的另一項重要增補。我們對其持續強勁的表現感到鼓舞,這展現其對醫療提供者及其病患具吸引力的價值主張。在腫瘤及其他專科領域,我們的配送能力、數據驅動洞察、臨床專業與具經驗的支援型醫療提供者,使我們能為客戶創造價值並改善病患取得照護的可近性。

  • Within our biopharma services platform, we continue to see strong demand for solutions that improve medication access and affordability. As therapeutic innovation accelerates and the treatment landscape becomes more complex, our differentiated solutions are helping translate that innovation into meaningful access for patients. Our platform connects providers, pharmacies, payers and manufacturers through technology that's embedded in prescribing and dispensing workflows.

    在我們的生物製藥服務平台內,我們持續看到對於可提升用藥可近性與可負擔性的解決方案有強勁需求。隨著治療創新加速、治療版圖日益複雜,我們具差異化的解決方案正協助將創新轉化為病患可實際取得的有意義可近性。我們的平台透過嵌入處方與調劑工作流程的技術,連結醫療提供者、藥局、付款方與製造商。

  • We continue to expand our payer network, which now includes payers that represent 96% of U.S. prescription volume. This connectivity enables us to simplify administrative processes and address financial barriers at scale, helping patients start and stay on therapy while supporting biopharma partners across their product life cycles.

    我們持續擴大付款方網絡,目前已涵蓋代表美國處方量96%的付款方。此一連結性使我們能簡化行政流程,並以規模化方式解決財務障礙,協助病患開始並持續接受治療,同時在產品生命週期各階段支援生物製藥合作夥伴。

  • The momentum across our biopharma services platforms continues to be broad-based. During the quarter, we added 67 new programs across 58 unique brands, representing a diversified portfolio of therapeutic areas in both access and affordability. We expanded connectivity with providers, with more of them exploring our automated solutions, including our recently introduced medical prior authorization capabilities. We also saw growth in services that provide dedicated reimbursement specialists to help providers navigate insurance coverage and reimbursement challenges, reinforcing the value of hands-on expertise alongside our automated solutions.

    我們生物製藥服務平台的動能持續且全面。本季我們新增67個新方案,涵蓋58個不同品牌,代表在可近性與可負擔性兩方面、跨多元治療領域的分散化產品組合。我們也擴大與醫療提供者的連結,更多提供者正在探索我們的自動化解決方案,包括我們近期推出的醫療事前授權能力。我們亦看到提供專屬給付/報銷專員的服務成長,協助提供者因應保險給付範圍與報銷挑戰,進一步凸顯在自動化解決方案之外,結合實務專業支援的價值。

  • Looking ahead, we remain focused on leveraging technology and automation to enhance the functionality of our solutions and streamline workflows. By simplifying routine processes and complementing them with specialized expertise where greater support is needed, we can address a broad range of access and affordability barriers and strengthen the value we deliver to biopharma partners, providers and patients.

    展望未來,我們仍聚焦運用科技與自動化來提升解決方案功能並精簡工作流程。透過簡化例行流程,並在需要更高支援之處以專業能力加以補強,我們得以因應廣泛的可近性與可負擔性障礙,並強化我們為生物製藥合作夥伴、醫療提供者與病患所帶來的價值。

  • Let's turn to North American distribution. Our pharmaceutical distribution business continues to perform well, supported by stable market fundamentals, operational excellence and our differentiated customer value proposition. Recently, we announced an extension of our pharmaceutical distribution relationship with CVS Health. This agreement reflects the strength of our long-standing partnership of more than 25 years, the value of our distribution capabilities and our ability to support customers at scale with reliability, efficiency and service excellence. We value our relationship with customers across the health care ecosystem and remain focused on supporting their growth through consistent execution and the highest levels of service.

    接下來談北美分銷業務。我們的藥品分銷業務持續表現良好,受惠於穩健的市場基本面、卓越的營運執行,以及我們具差異化的客戶價值主張。近期,我們宣布延長與CVS Health的藥品分銷合作關係。此協議反映我們超過25年的長期夥伴關係之強度、我們分銷能力的價值,以及我們以可靠性、效率與卓越服務在規模化支援客戶的能力。我們重視與醫療照護生態系中各類客戶的關係,並將持續透過一致的執行與最高水準的服務來支持其成長。

  • Across this segment, we continue to see strong momentum, reflecting our unwavering commitment to customers, the consistent delivery of high-quality service and a disciplined focus on operational excellence. This performance enables us to reinvest in the business, including our distribution network, supply chain capabilities and technology infrastructure, which further strengthen the reliability, efficiency and scale of our platform and position us to deliver sustainable long-term growth.

    在此分部,我們持續看到強勁動能,反映我們對客戶的堅定承諾、持續交付高品質服務,以及對營運卓越的嚴謹聚焦。此一表現使我們得以再投資於業務,包括我們的分銷網絡、供應鏈能力與科技基礎設施,進一步強化平台的可靠性、效率與規模,並使我們具備實現可持續長期成長的定位。

  • The strength of our business and our diversified capabilities position us well to drive continued growth amid evolving industry trends and a dynamic policy environment. We are committed to working closely with policymakers to advance thoughtful reforms that support patients and providers, expand access to care and improve health outcomes.

    我們業務的實力與多元化能力,使我們在產業趨勢演變與政策環境動態變化之下,仍具備推動持續成長的良好定位。我們承諾與政策制定者密切合作,推動審慎周延的改革,以支持病患與醫療提供者、擴大照護可近性並改善健康結果。

  • In closing, our strong second quarter results build on a strong record of execution and growth. We're pleased with the momentum of the underlying business, reinforcing our commitment to our strategic priorities. The Precision Medicine Group acquisition and our proposed investment in Option Care Health represent significant progress in expanding our capabilities and investing in areas of compelling long-term opportunity. Looking ahead, we're confident in our ability to deliver sustainable growth and long-term shareholder value.

    最後,我們強勁的第二季成果建立在長期穩健的執行與成長紀錄之上。我們對核心業務的動能感到滿意,並再次強化我們對策略優先事項的承諾。收購Precision Medicine Group以及我們擬議對Option Care Health的投資,代表我們在擴充能力並投資於具吸引力的長期機會領域方面取得重大進展。展望未來,我們對於交付可持續成長與長期股東價值的能力充滿信心。

  • With that, let me turn it over to Kenny.

    接下來,我把時間交給Kenny。

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Thank you, Brian, and good afternoon, everyone. We delivered a strong second quarter, supported by broad-based growth across the enterprise. This quarter's performance builds on the momentum from last quarter, resulting in a strong first half of fiscal 2027 and reinforcing our confidence in the opportunities ahead.

    謝謝你,Brian,各位下午好。我們交出強勁的第二季表現,受惠於全企業範圍的廣泛成長。本季表現延續上季動能,使2027會計年度上半年表現強勁,並強化我們對未來機會的信心。

  • Before I turn to our adjusted results, I want to highlight the two important transactions we announced recently. As Brian mentioned in his opening remarks, we are pleased to have completed the acquisition of Precision Medicine Group for approximately $2.25 billion. The business will report within our Oncology & Multispecialty segment, further expanding the breadth of solutions we provide across our oncology, multispecialty and biopharma services. We expect the transaction to be accretive and reinforce our long-term growth profile.

    在我談到調整後結果之前,我想先強調我們近期宣布的兩項重要交易。如Brian在開場致詞中提到,我們很高興已以約22.5億美元完成對Precision Medicine Group的收購。該業務將納入我們的「腫瘤與多專科」分部報告,進一步擴大我們在腫瘤、多專科與生物製藥服務方面所提供解決方案的廣度。我們預期此交易將具增益效果(accretive),並強化我們的長期成長輪廓。

  • We estimate the acquisition will contribute approximately $0.10 to $0.20 of adjusted earnings per diluted share in fiscal '27, with contributions more heavily weighted towards the fourth quarter. By the end of year 3, we estimate accretion of approximately $1.60 to $1.80. We funded the transaction with cash, reflecting the strength and flexibility of our balance sheet.

    我們估計該收購在2027會計年度將為稀釋後每股調整後盈餘貢獻約0.10至0.20美元,且貢獻將更偏重於第四季。至第3年年底,我們估計增益約為1.60至1.80美元。我們以現金為該交易提供資金,反映我們資產負債表的實力與彈性。

  • Additionally, we announced that we have entered into a definitive agreement to invest approximately $1.4 billion for a 49% minority interest in Option Care Health. The transaction aligns with our strategy to expand access to innovative therapies and our commitment to advance care in lower-cost community settings. The transaction is expected to close during the first half of calendar year '27, subject to customary closing conditions, including approval by Option Care Health's shareholders and the receipt of required regulatory approvals. Our current outlook does not contemplate contributions from Option Care Health.

    此外,我們宣布已簽訂具約束力的最終協議,將投資約14億美元以取得Option Care Health 49%的少數股權。此交易符合我們擴大創新療法可近性的策略,以及我們推動在成本較低的社區場域提供照護的承諾。該交易預計於曆年2027年上半年完成交割,惟須符合慣常交割條件,包括取得Option Care Health股東核准及必要的監管核准。我們目前的展望未納入Option Care Health的貢獻。

  • Together, these investments reinforce our disciplined approach for capital deployment. First, we prioritize growth opportunities that align with our strategy, complement our portfolio and meet our financial criteria for attractive returns and long-term value creation. Second, we remain committed to returning capital to shareholders through a combination of share repurchases and a growing dividend. Lastly, we maintain a strong balance sheet supported by robust free cash flow generation and liquidity. This enables us to continue investing in and growing the business.

    合計而言,這些投資強化了我們在資本配置上的紀律作法。第一,我們優先考量與策略一致、能補強投資組合,且符合我們財務標準、可帶來具吸引力報酬與長期價值創造的成長機會。第二,我們仍致力於透過股票回購與股利成長的組合方式回饋股東。最後,我們維持強健的資產負債表,並由強勁的自由現金流創造能力與流動性所支撐。這使我們能持續投資並擴大業務。

  • Unless otherwise noted, my comments today will refer to our adjusted results. Let me turn to our second quarter consolidated performance. Revenues increased 8% to $111 billion, with growth across all four operating segments. Growth was driven by higher prescription volumes in North American Pharmaceutical and continued strength in Oncology & Multispecialty. This was partially offset by lower contributions from branded pharmaceuticals and continued branded-to-generic conversions.

    除非另有說明,我今天的評論將以我們的調整後結果為準。接著談第二季合併表現。營收成長8%至1,110億美元,四個營運分部皆有成長。成長主要由北美藥品業務處方量增加,以及腫瘤與多專科業務持續強勁所帶動。部分被品牌藥貢獻下降以及品牌轉學名藥的持續轉換所抵銷。

  • Gross profit increased 10% to $3.9 billion, driven by growth in North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. The increase reflects higher prescription volumes and continued strength in specialty as we leverage our scale and distribution capabilities. Operating expenses increased 8% to $2.1 billion, reflecting higher expenses to support growth across the business. We remain focused on driving productivity and strengthening our network while maintaining expense discipline and investing to enhance how we serve our customers and drive future growth.

    毛利成長10%至39億美元,主要由北美藥品、腫瘤與多專科,以及處方技術解決方案的成長所帶動。此增幅反映處方量提升,以及我們運用規模與分銷能力帶動專科領域持續強勁。營業費用成長8%至21億美元,反映為支援全業務成長而增加的費用。我們仍聚焦提升生產力並強化網絡,同時維持費用紀律,並投資以提升我們服務客戶的方式與推動未來成長。

  • We demonstrated strong operating leverage during the quarter, with operating expenses as a percentage of gross profit improving by approximately 141 basis points year-over-year. Operating profit increased 13% to $1.9 billion, driven by North American Pharmaceutical, Prescription Technology Solutions and Oncology & Multispecialty. Interest expense was $103 million, reflecting financing activities completed in support of the planned Medical-Surgical Solutions separation.

    本季我們展現強勁的營運槓桿,營業費用占毛利比率較去年同期改善約141個基點。營業利益成長13%至19億美元,主要由北美藥品、處方技術解決方案,以及腫瘤與多專科所帶動。利息費用為1.03億美元,反映為支援規劃中的醫療-外科解決方案分拆所完成的融資活動。

  • The effective tax rate in the second quarter was 17.8%, which included net discrete tax benefits of $105 million. As a reminder, our effective tax rate can vary quarter-to-quarter, driven by timing and the amount of discrete tax items. Diluted weighted average shares were 116.7 million, a decrease of 6%, reflecting continued share repurchase activity. Adjusted earnings per diluted share increased 18% to $11.68, driven by strong operating performance across North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions segment and the benefit of a lower share count. Excluding the prior year contribution from the $25 million Norway divestiture and the net gains of $51 million from the sale of an equity investment and market positions within the US Oncology Network, adjusted earnings per diluted share increased 24%.

    第二季的有效稅率為 17.8%,其中包含 1.05 億美元的淨一次性(離散)稅務利益。提醒一下,我們的有效稅率可能會在各季度之間波動,主要受時點因素以及一次性稅務項目的金額所驅動。稀釋後加權平均股數為 1.167 億股,下降 6%,反映持續進行的股票回購活動。稀釋後每股調整後盈餘成長 18% 至 11.68 美元,主要受北美藥品、腫瘤與多專科以及處方技術解決方案部門的強勁營運表現,以及股數下降帶來的效益所帶動。若排除前一年 2,500 萬美元挪威資產剝離的貢獻,以及在美國腫瘤網路(US Oncology Network)內出售一項股權投資與市場部位所產生的 5,100 萬美元淨收益,稀釋後每股調整後盈餘成長 24%。

  • Let me now turn to our segment results. Starting with North American Pharmaceutical segment. Revenues were $91.4 billion, an increase of 6%, driven by higher prescription volumes, including growth in specialty products and GLP-1 medications. This was partially offset by lower contributions from branded pharmaceuticals and continued branded-to-generic conversions. Lower branded pharmaceutical pricing as a result of wholesale acquisition cost decreases in January 2026 reduced year-over-year revenue growth by approximately 4%.

    接下來我將說明各部門的業績表現。先從北美藥品部門開始。營收為 914 億美元,成長 6%,主要由處方量增加所帶動,其中包括專科產品與 GLP-1 藥物的成長。上述成長部分被品牌藥品貢獻下降以及持續的品牌轉學名藥(branded-to-generic)轉換所抵銷。由於 2026 年 1 月批發取得成本(WAC)下調導致品牌藥品價格降低,使得年對年營收成長約減少 4%。

  • Consistent with prior periods, these pricing changes did not have a meaningful impact on the segment operating profit. Revenues from GLP-1 medication distribution were $16 billion in the quarter, an increase of approximately $3 billion or 26% versus the prior year. Sequentially, GLP-1 revenues increased 8%. Demand and volumes across the category remain strong, with quarter-to-quarter variability based on payer dynamics and patient utilization.

    與先前期間一致,這些價格變動對該部門的營業利益並未造成顯著影響。本季 GLP-1 藥物配送營收為 160 億美元,較去年同期增加約 30 億美元或 26%。按季比較,GLP-1 營收成長 8%。該類別的需求與量能仍然強勁,但各季度之間會因付款方動態與病患使用情況而有所波動。

  • Operating profit increased 22% to $1 billion. Growth was driven by specialty distribution, including health system and strategic accounts. Our distribution platforms support a broad evolving portfolio of products, including increasingly complex therapies. Our reach and expertise allows us to effectively support these products as demand continues to grow.

    營業利益成長 22% 至 10 億美元。成長主要由專科配送所帶動,包括醫療體系與策略性客戶。我們的配送平台支援廣泛且持續演進的產品組合,其中包含日益複雜的療法。憑藉我們的覆蓋範圍與專業能力,隨著需求持續成長,我們得以有效支援這些產品。

  • Turning to Oncology & Multispecialty. Revenues were $15 billion, an increase of 24%, driven by growth from specialty product distribution and higher volumes across our provider platforms. We saw strong utilization within provider solutions, including distribution of Oncology & Multispecialty products. Operating profit increased 8% to $427 million. As a reminder, the prior year period included net gains of $51 million within the US Oncology Network. Excluding the net gains, operating profit increased by 23%.

    接著看腫瘤與多專科部門。營收為 150 億美元,成長 24%,主要由專科產品配送成長以及我們醫療提供者平台的量能提升所帶動。我們在提供者解決方案方面看到強勁的使用量,包括腫瘤與多專科產品的配送。營業利益成長 8% 至 4.27 億美元。提醒一下,去年同期在美國腫瘤網路內包含 5,100 萬美元的淨收益。若排除該淨收益,營業利益成長 23%。

  • Growth was driven by provider solutions businesses, including GPO services and higher specialty distribution volumes. We expanded our provider platforms through growth within existing practices and new provider additions. Utilization trends remain solid, with the same-store patient visits reaching their highest level in recent quarters across our networks.

    成長主要由提供者解決方案業務所帶動,包括 GPO 服務以及更高的專科配送量。我們透過既有診所的成長與新增提供者加入,擴大了提供者平台。使用量趨勢仍然穩健,同店病患就診次數在我們的網路中達到近幾季以來的最高水準。

  • In Prescription Technology Solutions, revenues were $1.5 billion, an increase of 10%, driven by higher prescription volume in third-party logistics and access solutions. This was partially offset by lower contributions from hub dispensing services. Operating profit increased 18% to $307 million, driven by higher demand across our access solutions, including prior authorization services.

    在處方技術解決方案方面,營收為 15 億美元,成長 10%,主要由第三方物流與可近性(access)解決方案的處方量增加所帶動。上述成長部分被樞紐配藥(hub dispensing)服務貢獻下降所抵銷。營業利益成長 18% 至 3.07 億美元,主要由我們的可近性解決方案需求提升所帶動,其中包括事前授權(prior authorization)服務。

  • We continue to see volume growth across services for both GLP-1 and non-GLP-1 medications, including contributions from the CMS Medicare GLP-1 Bridge program, which started on July 1. We also saw solid performance across other therapeutic categories as we added new brands and expanded existing programs across the platform.

    我們持續看到針對 GLP-1 與非 GLP-1 藥物的各項服務量能成長,其中包括自 7 月 1 日開始的 CMS Medicare GLP-1 Bridge 計畫所帶來的貢獻。隨著我們新增品牌並在平台上擴大既有方案,我們在其他治療領域也看到穩健表現。

  • Our solutions support biopharma partners across the life cycle of a product. As therapies move from launch to broader adoption and maturity, our platform is well positioned to support the evolving need for access, affordability and adherence solutions.

    我們的解決方案可在產品生命週期各階段支援生物製藥合作夥伴。隨著療法從上市推進到更廣泛採用並走向成熟,我們的平台具備良好定位,可支援可近性、可負擔性與用藥依從性解決方案等不斷演進的需求。

  • Turning to Medical-Surgical Solutions. Revenues were $3.1 billion, an increase of 5%, driven by growth across extended and ambulatory care channels. This represents continued sequential improvement in revenue growth trends, supported by higher volumes across multiple product categories, including specialty pharmaceuticals. Operating profit decreased 10% to $225 million, driven by lower contributions from the ambulatory care channel due to product mix, partially offset by growth in the extended care channel. We are pleased with the growth in the extended care channel, supported by higher demand across several product categories.

    接著看醫療-外科解決方案部門。營收為 31 億美元,成長 5%,主要由長期照護與門診照護通路的成長所帶動。在多個產品類別(包括專科藥品)量能提升的支撐下,這代表營收成長趨勢持續呈現按季改善。營業利益下降 10% 至 2.25 億美元,主要因門診照護通路受產品組合影響而貢獻降低;部分被長期照護通路的成長所抵銷。我們對長期照護通路的成長感到滿意,該成長受多個產品類別需求提升所支撐。

  • Wrapping up our review with Corporate. Corporate expenses were $147 million, a decrease of 3%, reflecting disciplined expense management, partially offset by continued investment in technology capabilities to support the business. Let me turn to cash and capital allocation. We ended the quarter with $6.5 billion in cash and cash equivalents and total liquidity of approximately $11.5 billion, which is above the minimum threshold. Our balance sheet remains robust and provides ample capacity to support our strategic priorities.

    最後回顧公司層級(Corporate)。公司費用為 1.47 億美元,下降 3%,反映嚴謹的費用管理;部分被持續投資於技術能力以支援業務所抵銷。接下來談現金與資本配置。本季末我們持有 65 億美元的現金及約當現金,總流動性約 115 億美元,高於最低門檻。我們的資產負債表仍然穩健,並提供充足的能力以支援我們的策略優先事項。

  • During the second quarter, we delivered free cash flow of $2.9 billion, including $123 million in capital expenditures. Our strong cash generation provides capacity to reinvest in the business, including technology, infrastructure and operational capabilities. We also maintain flexibility to continue to execute our capital allocation priorities, including share repurchases. During the quarter, we returned $990 million to shareholders through a combination of share repurchases and dividend payments. We remain disciplined in deploying capital towards opportunities that offer attractive returns and long-term shareholder value.

    第二季我們創造自由現金流 29 億美元,其中包含 1.23 億美元的資本支出。強勁的現金創造能力使我們得以再投資於業務,包括技術、基礎設施與營運能力。我們也維持彈性以持續執行資本配置優先事項,包括股票回購。本季我們透過股票回購與股利發放的組合,向股東回饋 9.90 億美元。我們在資本部署上仍保持紀律,將資金投入於可提供具吸引力回報與長期股東價值的機會。

  • Turning now to our fiscal '27 outlook. We delivered strong results through the first half of the year, including second quarter performance that exceeded our expectations. Based on these results, our outlook for the remainder of the year, we are raising our fiscal '27 adjusted earnings per diluted share outlook to $45.60 to $46.40.

    接下來談我們 2027 會計年度('27)的展望。我們在上半年交出強勁成果,其中第二季表現超出我們的預期。基於這些結果以及我們對今年剩餘期間的展望,我們將 2027 會計年度稀釋後每股調整後盈餘(adjusted EPS)展望上調至 45.60 至 46.40 美元。

  • We entered the second half with confidence in the fundamentals of our business and our ability to execute against our priorities. Our updated outlook implies adjusted EPS growth of 17% to 19%. Excluding the impact of the Norway divestiture and the net gains within the US Oncology Network in fiscal '26, our outlook implies adjusted EPS growth of 19% to 21%, which is well above our long-term growth target of 13% to 16%. For fiscal '27, we anticipate revenue growth of 6% to 10% and operating profit growth of 12% to 16%.

    我們以對業務基本面及執行優先事項能力的信心進入下半年。我們更新後的展望意味著調整後 EPS 成長 17% 至 19%。若排除 2026 會計年度挪威資產剝離的影響,以及美國腫瘤網路內的淨收益影響,我們的展望意味著調整後 EPS 成長 19% 至 21%,明顯高於我們 13% 至 16% 的長期成長目標。對於 2027 會計年度,我們預期營收成長 6% 至 10%,營業利益成長 12% 至 16%。

  • Let me provide additional context on our segment outlook. In North American Pharmaceutical, we anticipate revenue growth of 5% to 9% and operating profit growth of 14% to 18%. The outlook reflects broad-based strength across the business, including strong performance in the second quarter. We anticipate the momentum will be supported by stable market trends, including growth in prescription volume, increasing demand for specialty and branded medications, including GLP-1s, and benefits of improved productivity, driving operational leverage, underpinned by disciplined execution across sourcing and distribution. The outlook also contemplates continued impact on segment revenue from lower branded pharmaceutical pricing following wholesale acquisition cost decreases.

    我再補充一些各部門展望的背景說明。在北美藥品部門,我們預期營收成長 5% 至 9%,營業利益成長 14% 至 18%。此展望反映業務各面向的廣泛強勁表現,包括第二季的強勁績效。我們預期動能將受穩定的市場趨勢所支撐,包括處方量成長、對專科與品牌藥物(包括 GLP-1)的需求增加,以及生產力改善帶來的效益、推動營運槓桿;其基礎來自於在採購與配送方面的嚴謹執行。此展望亦納入在批發取得成本下調後,品牌藥品價格降低對部門營收的持續影響。

  • Looking ahead to the second half of the fiscal year, we anticipate accelerated investments focused on enhancing our capabilities and supporting business growth. Additionally, the outlook reflects our continued strong relationship with customers, including customer wins and renewals of existing relationships.

    展望本財政年度下半年,我們預期將加速投資,重點在於強化我們的能力並支持業務成長。此外,展望亦反映我們與客戶持續維持強勁關係,包括贏得新客戶以及既有合作關係的續約。

  • Turning to Oncology & Multispecialty. We anticipate revenue growth of 20% to 24% and operating profit growth of 18% to 22%. Excluding the net gains of $51 million in fiscal '26, our outlook implies operating profit growth of 22% to 26%. The outlook is supported by provider solutions, including specialty distribution and GPO services, and our broader portfolio of Oncology & Multispecialty offerings.

    接著談腫瘤與多專科(Oncology & Multispecialty)。我們預期營收成長20%至24%,營業利益成長18%至22%。若排除財年'26的5,100萬美元淨收益,我們的展望意味著營業利益成長22%至26%。此展望由醫療提供者解決方案所支撐,包括專科配送與GPO服務,以及我們更廣泛的腫瘤與多專科產品組合。

  • We continue to see expansion across our provider platforms through both new additions and growth within existing practices. Within our retina and ophthalmology platform, the PRISM Vision Group recently welcomed Spectrum Vision Partners, further strengthening its presence in the Mid-Atlantic region. We anticipate some variability from quarter-to-quarter, including investments weighted towards the earlier part of the second half.

    我們持續看到醫療提供者平台的擴張,來源包括新增加入以及既有診所內部的成長。在我們的視網膜與眼科平台方面,PRISM Vision Group近期迎來Spectrum Vision Partners,進一步強化其在美國中大西洋地區的布局。我們預期季度之間可能出現一定波動,包括投資較偏重於下半年較早期的季度。

  • In Prescription Technology Solutions, we anticipate revenue growth of 2.5% to 6.5% and operating profit growth of 11% to 15%. We expect continued growth in access and affordability solutions, supported by demand across GLP-1 medications and other therapeutic categories. As products move through their life cycle, the type and level of support required could change. This creates opportunities for onboarding of new programs and expanding the services provided through existing relationships. These dynamics can also create quarterly variability based on utilization, product launch timing, shifts in payer landscape and changes in program requirements.

    在處方科技解決方案(Prescription Technology Solutions)方面,我們預期營收成長2.5%至6.5%,營業利益成長11%至15%。我們預期可近性與可負擔性解決方案將持續成長,並受惠於GLP-1藥物及其他治療類別的需求。隨著產品進入其生命週期的不同階段,所需支援的類型與程度可能改變。這將帶來導入新方案以及透過既有合作關係擴大服務內容的機會。這些動態也可能因使用量、產品上市時點、付款方環境變化以及方案需求變動,而造成季度間的波動。

  • For example, we are in the early phases of supporting the CMS Medicare GLP-1 Bridge program. Following initial strong demand, prior authorization volumes have begun to normalize, and we will continue to monitor trends as the program progresses. Looking to the second half, the fourth quarter historically benefits from contribution from annual reverification programs, and we anticipate a similar cadence this year.

    例如,我們正處於支援CMS Medicare GLP-1 Bridge計畫的早期階段。在初期需求強勁之後,事前授權(prior authorization)量已開始回歸常態;隨著計畫推進,我們將持續監測趨勢。展望下半年,第四季歷來會受惠於年度重新驗證(reverification)計畫的貢獻,我們預期今年也將呈現類似節奏。

  • Moving now to MedSurg. We anticipate revenue growth of 1% to 6% and operating profit to range from a 4% decline to flat. Our outlook reflects the breadth of the business across alternate sites of care, including inventory and extended care, consumer health and at-home care. To support future growth, we implemented initiatives across the business focused on driving growth opportunities, building the commercial pipeline and driving operating efficiency. We expect the initiatives implemented during the first half to support growth and performance through the remainder of the year.

    接著談MedSurg。我們預期營收成長1%至6%,營業利益介於下滑4%至持平。我們的展望反映該業務在替代照護場域的廣泛布局,包括庫存與延伸照護、消費者健康以及居家照護。為支持未來成長,我們在全業務推動多項措施,聚焦於推動成長機會、建立商業管線並提升營運效率。我們預期上半年所實施的措施,將在今年剩餘期間持續支持成長與表現。

  • Our second half results can also be impacted by the annual illness season. As a reminder, each illness season is unique. The timing, severity and duration can vary from year to year. In Corporate, we anticipate expenses at the high end of the $580 million to $640 million range. As a reminder, we completed our exit from Norway in January. In fiscal '26, the Norway business contributed $74 million of operating profit, including $28 million in the fiscal third quarter.

    我們下半年的結果也可能受到年度疾病季節的影響。提醒一下,每一個疾病季節都有其獨特性。其發生時點、嚴重程度與持續時間每年都可能不同。在公司層面(Corporate),我們預期費用將落在5.8億至6.4億美元區間的高端。提醒一下,我們已於1月完成退出挪威市場。在財年'26,挪威業務貢獻7,400萬美元的營業利益,其中包含財年第三季的2,800萬美元。

  • Turning now to items below the line. We expect interest expense to be in the high end of $380 million to $420 million, reflecting higher borrowing rates associated with financing activities. We expect income attributable to noncontrolling interest of $290 million to $320 million, which includes the minority ownership interest by Apollo in our MedSurg business.

    接著談損益表線下項目(below the line)。我們預期利息費用將落在3.8億至4.2億美元區間的高端,反映與融資活動相關的借款利率較高。我們預期歸屬於非控制權益的利益為2.9億至3.2億美元,其中包含Apollo在我們MedSurg業務中的少數股權。

  • We anticipate a full year effective tax rate of 18% to 19%. We expect quarterly tax rate phasing to be broadly similar to fiscal '26, with a higher tax rate in the third quarter than the fourth quarter due to the timing of discrete tax items.

    我們預期全年有效稅率為18%至19%。我們預期季度稅率的分布大致與財年'26相近;由於一次性稅務項目的時點因素,第三季稅率將高於第四季。

  • Wrapping up our outlook with cash flow and capital deployment. We anticipate free cash flow of approximately $4.5 billion to $4.9 billion. As a reminder, cash flow can vary from quarter-to-quarter based on timing, including day of the week a quarter ends.

    最後以現金流與資本部署總結我們的展望。我們預期自由現金流約為45億至49億美元。提醒一下,現金流可能因時點因素而在季度間波動,包括季度結束日落在星期幾。

  • We remain disciplined on capital allocation. We expect to repurchase approximately $5 billion of shares during fiscal '27. Through the first half, we purchased approximately $3.4 billion of shares at an average price of approximately $818 per share, completing a significant portion of our planned full year share repurchases. We estimate diluted weighted average shares outstanding to be in the range of 115.5 million to 117.5 million.

    我們在資本配置上仍保持紀律。我們預期在財年'27回購約50億美元的股票。截至上半年,我們已以每股約818美元的平均價格回購約34億美元股票,完成了全年計畫回購的重要部分。我們估計稀釋後加權平均流通股數將介於1.155億至1.175億股。

  • In closing, I am pleased with the performance through the first half of the year and the progress we are making across the business. We entered the second half with strong momentum, clear priorities and confidence in our outlook. We remain focused on execution and delivering long-term value for our shareholders.

    總結來說,我對上半年表現以及我們在各項業務上的進展感到滿意。我們以強勁動能、明確優先事項以及對展望的信心進入下半年。我們仍將專注於執行,並為股東創造長期價值。

  • With that, let's move to Q&A.

    接下來,我們進入問答環節。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Glen Santangelo, Barclays.

    Barclays的Glen Santangelo。

  • Glen Santangelo - Equity Analyst

    Glen Santangelo - Equity Analyst

  • Thanks for taking my questions. Just two quick ones for me. Brian and Kenny, I'm trying to understand these 2 acquisitions you did, Precision Medicine Group and Option Care Health. I'm just trying to -- I want to make sure I'm clear on how these businesses will weave through the reporting segments of the company and the potential impact that, that may have on your margins.

    謝謝讓我提問。我這邊只有兩個簡短問題。Brian和Kenny,我想了解你們做的兩項收購:Precision Medicine Group和Option Care Health。我想確認我是否清楚,這些業務將如何納入公司各報導分部,以及這可能對你們的利潤率帶來的潛在影響。

  • And as I think to model calendar '27, not that you want to give any forward guidance, I'm just trying to think through these ancillary services that you're acquiring. And then secondly, as we have a whole slate of biosimilars set to be launched here in the next 12 months, I'm just trying to think about the puts and takes on your margins across your 2 segments, Onco & Multispecialty and Prescription Technologies. Thanks so much.

    另外,當我思考要建模日曆年'27時——並不是說你們要提供任何前瞻指引——我只是想把你們正在收購的這些周邊服務(ancillary services)梳理清楚。第二點是,未來12個月將有一整批生物相似藥(biosimilars)準備上市,我想了解這對你們兩個分部——腫瘤與多專科,以及處方科技——的利潤率會有哪些拉抬與壓力(puts and takes)。非常感謝。

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Why don't I start by maybe reviewing the strategic rationale for these and then, Kenny, you can comment on the question about where it reports and the margin profiles. So Precision for Medicine Group (sic - Precision Medicine Group), which we closed earlier this week, very excited about. It's really composed of two different business segments: Precision for Medicine, which provides global clinical research, translational science and laboratory capabilities with deep oncology experience and trials active in more than 30 countries.

    不如我先從回顧這些交易的策略理由開始,接著Kenny你再就報導歸屬與利潤率特性回答。Precision for Medicine Group(註:Precision Medicine Group),我們在本週稍早完成交割,對此非常興奮。它主要由兩個不同的業務分部構成:Precision for Medicine,提供全球臨床研究、轉譯科學與實驗室能力,並在腫瘤領域具備深厚經驗,試驗在30多個國家進行。

  • We really see that as being highly complementary to our oncology strategy, complementing USON, the joint venture we have with SCRI. And some of the site management and CRO lite-ish skills that SCRI had is now really accelerated with the acquisition of Precision for Medicine. And so as we think about the oncology strategy holistically, we think this is a really, really complementary piece to the assets that we currently have.

    我們認為這與我們的腫瘤策略高度互補,可補強USON——也就是我們與SCRI的合資企業——的布局。SCRI原本具備的一些站點管理與偏CRO-lite的能力,透過收購Precision for Medicine,如今得以大幅加速。因此,當我們以整體角度思考腫瘤策略時,我們認為這會是對我們現有資產非常、非常互補的一塊拼圖。

  • And then the other side of Precision is Precision AQ, which is a leading market access, health economics and commercialization services platform, which we think is highly complementary to our access and affordability capabilities and just gives us a broader portfolio or suites of solutions to support our biopharma partners as they commercialize over the life cycle of their products.

    Precision的另一部分是Precision AQ,這是一個領先的市場准入、健康經濟學與商業化服務平台;我們認為它與我們的可近性與可負擔性能力高度互補,並讓我們擁有更廣泛的產品組合或解決方案套件,以在合作夥伴的產品生命週期各階段,支持我們的生物製藥合作夥伴進行商業化。

  • So that was kind of the strategic rationale. It's really anchored in our two core growth strategies of oncology and serving biopharma. Both of these businesses will report through the O&M segment. And would you like to comment?

    所以那算是策略上的理由。這確實是以我們兩大核心成長策略為根基:腫瘤學以及服務生物製藥。這兩項業務都將透過 O&M 部門進行揭露。你想評論一下嗎?

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Yeah. So for PMG, just a couple of things on this one. So as Brian mentioned, very pleased to acquire PMG. We anticipate the transaction to be accretive in the current fiscal year and beyond. A purchase price of roughly $2.25 billion, from a financing source standpoint, this is all funded with cash given the strength of our balance sheet. Reporting standpoint, PMG will be reported within the O&M segment. From a financial profile standpoint, we estimate the acquisition will contribute approximately $0.10 to $0.20 of adjusted EPS in fiscal '27. And by the end of year three, we estimate accretion of approximately $1.60 to $1.80.

    是的。關於 PMG,這裡補充幾點。如 Brian 提到的,我們非常高興能收購 PMG。我們預期這筆交易在本財年以及往後都將具增益性(accretive)。收購價格約 22.5 億美元;就資金來源而言,鑑於我們資產負債表的強勁,這筆交易完全以現金支付。在揭露方面,PMG 將歸入 O&M 部門報告。就財務輪廓而言,我們估計該收購在 2027 財年將為調整後 EPS 貢獻約 0.10 至 0.20 美元。並且到第三年年底,我們估計增益約為 1.60 至 1.80 美元。

  • And like other prior M&A, the way to think about this is that we will anticipate a ramp-up in synergies as we continue to integrate the business within our platform. Obviously, there will be cost synergies assumed. But what Brian and I and the whole team are really excited about is the ability for us to enhance our clinical trial capabilities, serve even greater baskets of biopharma companies across more stages of clinical trial, being able to be part of a global platform and just overall strengthen the value proposition for a biopharma company.

    而且就像過去其他併購一樣,可以這樣理解:隨著我們持續把該業務整合進我們的平台,我們預期協同效益會逐步爬升。顯然會假設有成本協同。但 Brian、我以及整個團隊真正感到興奮的是:我們能提升臨床試驗能力,服務更多生物製藥公司、涵蓋臨床試驗更多階段,並能成為全球平台的一部分,整體上強化對生物製藥公司的價值主張。

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • And then to the margin profile question, if you remember at our Investor Day a couple of years ago, we laid out kind of on the left side of the slide, you have distribution and GPO with lower margin. As you progress into data services and SCRI, those tend to be higher margin, more complementary, more higher-margin businesses, and we would put PMG more on the right side of the chart.

    至於你問到的利潤率輪廓,如果你還記得我們幾年前的投資人日,我們在投影片左側大致列出:配送與 GPO 的利潤率較低。當你往資料服務與 SCRI 方向推進,這些通常是利潤率較高、互補性更強、屬於更高毛利的業務,而我們會把 PMG 放在圖表較右側的位置。

  • The second one you asked about was Option Care. I'll go quickly just in being conscious of time. Let's just remind everybody, this is a minority investment. We really are excited about this investment for a couple of reasons. As we think about the innovation pipeline, how specialty is evolving, we want to be an important player represented in all growth segments. And so given our expertise and scale in specialty, this made sense from that avenue.

    你問的第二個是 Option Care。我會快速帶過,顧及時間。先提醒大家,這是一項少數股權投資。我們對這項投資感到非常興奮,原因有幾個。當我們思考創新管線、以及專科領域如何演進時,我們希望在所有成長區隔中都能成為重要參與者。因此,考量我們在專科領域的專業與規模,從這個角度看這項投資是合理的。

  • We also have a very deep conviction about community-based care and providing care close to the home and in this case, even potentially in the home. And so as we thought our experience managing assets that are community practice-based and our experience in specialty and then the CD&R capabilities that come with it, we think this is just a good setup for us to complement the assets that we have. But this will be recorded under the equity method, so not really in any of the segment margin profiles.

    我們也非常堅信社區型照護的重要性,也就是在離家更近的地方提供照護;在這個案例中,甚至可能是在家中提供。因此,結合我們在管理以社區診所為基礎的資產方面的經驗、我們在專科領域的經驗,以及 CD&R 所帶來的能力,我們認為這對我們補強既有資產是一個很好的配置。但這將以權益法入帳,因此不會反映在任何部門的利潤率輪廓中。

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Yes, just to double click on the equity method. So from a geography standpoint, this will show up as other income within AOP. And from a BU standpoint, as Brian mentioned, not within the BU, but it will be reported within the Corporate segment.

    是的,補充說明一下權益法。就地理別呈現而言,這會在 AOP 中以其他收入呈現。就 BU 的角度,如 Brian 所說,不會歸在 BU 之內,而是會在公司(Corporate)部門中揭露。

  • Paula Adkison - Senior VP of Corporate Finance, Investor Relations & Strategic

    Paula Adkison - Senior VP of Corporate Finance, Investor Relations & Strategic

  • Next question, please.

    下一個問題,謝謝。

  • Operator

    Operator

  • Brian Tanquilut, Jefferies.

    Jefferies 的 Brian Tanquilut。

  • Brain Tanquilut - Analyst

    Brain Tanquilut - Analyst

  • Hey, good morning, guys, and congrats on the quarter. Maybe just a follow-up on the Option Care comments. I know you have a call option on it to acquire the remainder of the business at some point. Maybe, Brian, as we think about the strategy there, I hear your comments on specialty. But is there an overlay there for the oncology business that you're contemplating? Or maybe a different way of asking it strategically, other than just bringing in incremental revenue and access points, I mean, how are you thinking about overlaying that potentially eventually?

    各位早安,恭喜本季表現。我想追問一下關於 Option Care 的評論。我知道你們有一個買權(call option),可在某個時間點收購其餘的業務。Brian,從策略角度來看,我聽到你提到專科。但你們是否也在考慮把腫瘤業務的策略疊加進去?或者換個方式問,從策略上,除了帶來增量營收與接觸點之外,你們如何思考未來可能的整合疊加?

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Well, we have capabilities at McKesson, not just in oncology but in really all specialties, in rare and orphan therapies, and cell and gene therapies. And as we think about the future of how those markets evolve, we think having -- ultimately having access to our capabilities to provide those in ambulatory infusion, more community-based settings and in the home is going to be a growing and increasingly important channel. And so we just view this as very complementary to the channels and assets and reach that we have today.

    嗯,我們在 McKesson 的能力不僅在腫瘤領域,而是涵蓋幾乎所有專科,包括罕見與孤兒藥療法,以及細胞與基因療法。當我們思考這些市場未來如何演進時,我們認為——最終——能運用我們的能力,透過門診輸注、更多以社區為基礎的場域以及居家場景來提供這些治療,將會是一個成長且愈來愈重要的通路。因此,我們把這視為與我們目前既有的通路、資產與觸及範圍高度互補。

  • Paula Adkison - Senior VP of Corporate Finance, Investor Relations & Strategic

    Paula Adkison - Senior VP of Corporate Finance, Investor Relations & Strategic

  • Next question, please.

    下一個問題,謝謝。

  • Operator

    Operator

  • Elizabeth Anderson, Evercore.

    Evercore 的 Elizabeth Anderson。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • Hi, guys. Thanks so much for the question. Given the outperformance in North American Pharma, obviously growing well in excess of the long-term guide there. How do we think about the sustainability of that over the long term? It's obviously been several -- a while of this. So we think about sort of where the longer-term drivers of upside to that number might be. Or is this something that you think, okay, that's great, but there are potentially some other things to think about for fiscal '28 and beyond?

    嗨,各位。非常感謝讓我提問。鑑於北美藥品(North American Pharma)的表現超預期,顯然成長遠高於你們給出的長期指引。我們該如何看待這種表現的長期可持續性?這種情況已經持續好一段時間了。所以我們在思考,長期而言,推動該數字上行的驅動因素可能有哪些?或者你們認為,這當然很好,但在 2028 財年及之後可能還有一些其他因素需要考量?

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Yeah, I can start. So maybe first, let me get into the drivers of Q2, help you understand what drove the 22% AOP growth. And I'll talk more about how we're thinking about the rest of the year leaking into '28 as well. So as you think about Q2, we're pleased with the strong performance of NAPD. Revenue grew 6%, really driven by a few things. One is just broad-based growth, which included higher prescription volume, growth in specialty products and GLP-1s. And just to triple click on GLP-1, was roughly $16 billion of revenue for us, increased $3 billion or 26% year-on-year and 8% sequentially versus last quarter. We did have some WAC declines experienced in the quarter. However, as we mentioned before, it impacts more on the revenue line and less on the operating profit line.

    好的,我可以先回答。也許首先,我先談談第二季的驅動因素,幫你理解是什麼帶動了 AOP 22% 的成長。我也會再多談一些我們如何看待今年剩餘期間,以及延伸到 2028 財年的影響。就第二季而言,我們對 NAPD 的強勁表現感到滿意。營收成長 6%,主要由幾個因素驅動。第一是廣泛性的成長,其中包括處方量提升、專科產品成長以及 GLP-1 的成長。再更深入談 GLP-1:我們在這部分的營收約 160 億美元,年增 30 億美元或 26%,且較上一季環比成長 8%。本季我們確實遇到一些 WAC 下滑。不過如我們先前提到的,它對營收端影響較大,對營業利益端影響較小。

  • Speaking of operating profit, it increased 22%, driven by growth in the distribution of specialty products, the health systems and strategic accounts. So overall, it was broad-based growth. So that's the beauty of our business. When you parlay a strong, healthy, broad-based growth with continued operational excellence and productivity within our supply chain ecosystem, we saw really nice operating leverage close to 150 bps, which was led our North America Pharmaceutical business.

    談到營業利益,它成長了 22%,主要由專科產品配送、醫療體系與策略性客戶的配送成長所帶動。因此整體而言是廣泛性的成長。這就是我們業務的優勢。當你把強勁、健康且廣泛的成長,與我們供應鏈生態系中持續的營運卓越與生產力提升結合起來,我們就看到了非常不錯的營運槓桿效應,接近 150 個基點,而這正是由我們北美藥品業務所帶動。

  • So overall, we're really pleased with the growth, the momentum and the durable profile of this business. As I think through the second half of the fiscal year, the outlook reflects continued broad-based strength across the business. We anticipate momentum to be supported by stable market trends, including prescription volume, increasing demand for specialty and branded medication, including GLP-1s and overall continued health of our supply chain.

    總體而言,我們對這項業務的成長、動能以及其穩健且具持久性的輪廓感到非常滿意。當我思考本財年下半年時,我們的展望反映出業務各面向仍將維持廣泛性的強勁表現。我們預期動能將受到穩定的市場趨勢支持,包括處方量、對專科與品牌藥品(包含 GLP-1)的需求增加,以及我們供應鏈整體持續健康。

  • It also incorporates a couple of other things, investments in the second half of the year. We are continuing to focus on automation, technology and business growth. And also, our outlook reflects continued strong relationship with our customers. So our outlook includes wins, renewals with existing relationships. As we mentioned earlier, we did renew our CVS contract, and that term starts in October 1. It runs through June of 2032, and that is also baked into our outlook guidance as well. So overall, we're pleased with the performance of our business.

    其中也納入了其他幾項內容,包括下半年的一些投資。我們將持續聚焦於自動化、科技以及業務成長。同時,我們的展望也反映出與客戶之間持續穩固的關係。因此,我們的展望包含了新增勝案,以及與既有合作關係的續約。如同先前提到的,我們已完成 CVS 合約續約,該合約期自 10 月 1 日開始。合約將延續至 2032 年 6 月,這也已納入我們的展望指引之中。總體而言,我們對業務表現感到滿意。

  • Operator

    Operator

  • Lisa Gill, JPMorgan.

    Lisa Gill,摩根大通。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • Thanks very much. I just want to follow up on a few things here. When I think about the North American Pharmaceutical performance and you highlighted the specialty tech health system, one, how are you thinking about potential changes around 340B? I know we had an election that happened yesterday, and perhaps some things are off the table. But how could that potentially impact the amount of volume that you see there?

    非常感謝。我想就這裡幾點再追問一下。當我思考北美製藥業務的表現,以及你提到的專科技術健康體系時,第一,你們如何看待 340B 相關的潛在變化?我知道我們昨天剛結束一場選舉,或許有些事情已不在討論範圍內。但這可能會如何影響你們在那裡看到的量能?

  • And kind of dovetailing to that, Brian, you talked about a dynamic policy environment. Can you maybe just update us on any of your thoughts now that we have an idea of what Congress is going to look like going into '27? Any changes that you're anticipating that could impact either side of your business?

    另外延伸這點,Brian,你談到政策環境是動態的。既然我們現在大致知道 2027 年前後國會的樣貌,你能否更新一下你目前的一些看法?你預期會有哪些變化,可能影響你們業務的任一端?

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Yeah. All right. Let me start with your first question on 340B. We obviously provide distribution services to contract pharmacies. We support covered entities. We support the biopharma manufacturers themselves. We also, as you know, Lisa, have a range of 340B-related services, including consulting and software to help manage the supply chain optimization.

    好的。我先從你第一個關於 340B 的問題開始。我們顯然為合約藥局提供配送服務。我們支援受涵蓋實體(covered entities)。我們也支援生物製藥製造商本身。此外,如你所知,Lisa,我們也提供一系列與 340B 相關的服務,包括顧問服務與軟體,用以協助管理供應鏈最佳化。

  • As we think about the potential for January 2027 implementation of a rebate model, and you've also got OPPS, I think the difficult thing to -- for us to kind of contemplate in this moment is how are these going to be effectuated or implemented, how are customers going to think about new choices. In the case of the rebate model, it's probably a cash, more of a cash issue. So we'll have to work with our customers as we always do. We'll work with them to administratively support what we need to administratively support. We'll work with them to make sure that they continue to have the success they need to have to be viable.

    當我們思考 2027 年 1 月可能導入的回饋(rebate)模式,以及同時還有 OPPS 時,我認為此刻我們較難評估的是:這些將如何被落實或執行、客戶將如何看待新的選擇。就回饋模式而言,可能更偏向現金流層面的議題。因此我們將一如既往與客戶合作。我們會與他們合作,在行政作業上支援我們需要支援的部分。我們也會與他們合作,確保他們能持續取得所需的成功、維持可行性。

  • But we really don't know what their response will be in terms of behaviorally trying to grow 340B, trying to migrate away. Do some 340B scripts go to the community? Or do they stay where they currently are? The thing for us is we are represented in all channels. And what we know is the script will still be there, and we'll be ready to receive it and support it in whatever channel we can.

    但就行為面而言,他們會如何回應——例如試圖擴大 340B、或試圖轉移離開——我們確實還不知道。部分 340B 處方是否會流向社區端?或是仍留在目前所在的通路?對我們而言,重點是我們在所有通路都有布局。而我們知道處方量仍會存在,我們也會準備好在任何可行的通路中接收並提供支援。

  • We're actively tracking this. We're very engaged. Depending on where the policy ultimately lands, we will use the capabilities of our company to help navigate both on behalf of the customers and on behalf of ourselves.

    我們正積極追蹤此事。我們也高度投入。最終政策落點取決於結果,我們將運用公司的能力,協助客戶以及我們自身共同因應。

  • To your bigger question of now that I've had 12 hours to absorb the election results, I don't think my view of any of the policy discussion is different than it would have been last quarter. It is a dynamic environment. We know that cost and quality and access and transparencies are going to still be issues of high interest in Capitol Hill from our regulators and our legislators. And we will be part of those conversations, now building new relationships, educating new members, advocating on behalf of what we think is important to helping health care address the challenges that we have, advocating for community-based providers because they're affordable and more accessible.

    至於你更大的問題——在我花了 12 小時消化選舉結果之後——我不認為我對任何政策討論的看法,會與上季相比有所不同。這是一個動態的環境。我們知道成本、品質、可近性與透明度,仍將是國會山莊、監管機關與立法者高度關注的議題。我們也會參與這些對話:建立新的關係、向新任議員說明、並就我們認為重要的事項進行倡議,以協助醫療體系應對我們面臨的挑戰;同時也為社區型服務提供者發聲,因為他們成本更可負擔、可近性也更高。

  • And we'll continue to build those relationships. And just like we have always done, we've always worked with both sides of the house. We've always worked to try to figure out how we do the right thing for the health care system, and that's what we'll continue to do.

    我們會持續建立這些關係。而且就像我們一直以來所做的,我們始終與兩黨合作。我們一直努力找出如何為醫療體系做正確的事,而這也將是我們持續的方向。

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Yes. Just a couple of things on 340B from my end. Regardless of how 340B plays out, the value of our distribution services remains intact. We'll continue to focus on providing our customers with the highest quality of service and support them with our products and diverse portfolio.

    是的。就我這邊再補充幾點關於 340B 的看法。無論 340B 最終如何發展,我們配送服務的價值仍然不變。我們將持續專注於為客戶提供最高品質的服務,並以我們的產品與多元化組合來支援他們。

  • And this is an important piece. We will get fairly compensated for the fair value of service we provide. At this time, we do not anticipate any material financial impact to our business, and as Brian said, we'll watch this very, very carefully.

    而這是一個重要重點。我們將就所提供服務的公允價值,獲得合理的報酬。目前我們不預期對業務造成任何重大的財務影響;正如 Brian 所說,我們會非常、非常密切地觀察。

  • Operator

    Operator

  • Kevin Caliendo, UBS.

    Kevin Caliendo,瑞銀。

  • Glen Santangelo - Equity Analyst

    Glen Santangelo - Equity Analyst

  • Hi, good afternoon. Thanks for taking my question. I'm going to take Elizabeth's question and ask it a little bit differently, which is, your LRP versus what you've done over the last year, two years or so, seems comically low. So maybe instead of asking what drove you to getting to, in this quarter, north of 20% EBIT growth, maybe, what needs to happen for you to actually grow North American Pharma inside the LRP? Like what's embedded there for that versus the market growth or whatever? Because it just seems that your ability to beat that is tremendously easy.

    嗨,午安。謝謝讓我提問。我想沿用 Elizabeth 的問題,但換個方式問:你們的 LRP 相較於過去一年、兩年左右的實際表現,看起來低得有點誇張。所以與其問是什麼驅動你們在本季達到超過 20% 的 EBIT 成長,不如問:要發生什麼情況,你們才會在 LRP 的框架內讓北美製藥業務成長?也就是說,相較於市場成長或其他因素,那裡面到底內含了什麼假設?因為看起來你們要超越那個目標實在太容易了。

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Yes. So I can start. So when we refer to the LRP, obviously, we're referring to the long-term targets. So I've reviewed our long-term business plan. I feel confident about the business fundamentals and our ability to execute against these long-term targets. For EPS, it was roughly 13% to 16%, just to remind everybody.

    好的,我可以先回答。當我們提到 LRP 時,顯然指的是長期目標。我已檢視我們的長期業務計畫。我對業務基本面以及我們達成這些長期目標的執行能力有信心。就 EPS 而言,提醒大家一下,目標大約是 13% 到 16%。

  • Looking at the long term, we anticipate the growth will be driven by the strength of our leading platforms in oncology, multi-specialty and biopharma solutions and supported by operating leverage and efficient capital deployment. We are well positioned to capture long-term growth through disciplined execution of strategic priorities and sustainable operational momentum. I just want to remind you that our long-term targets are long term in nature and not an indicator of short-term variations that incur -- that can occur within the business year-to-year.

    從長期來看,我們預期成長將由我們在腫瘤、多專科以及生物製藥解決方案等領先平台的實力所驅動,並由營運槓桿與有效的資本配置所支撐。透過對策略優先事項的紀律執行與可持續的營運動能,我們具備良好定位以掌握長期成長。我也想提醒各位,我們的長期目標本質上是長期的,並非用來反映業務在年度之間可能出現的短期波動指標。

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Yes. I just want to reflect on -- I think the performance we're enjoying now is an accumulation of years of focus on our strategic priorities, years of investment in technologies, whether that's physical distribution or robotic process automation or now large language models in AI that are translating from gross profit leverage ratios that Kenny reviewed. And I think it's just reflective of the great alignment and understanding of the team of how we need to show up every day for our customers, how we win new customers, win customers that are winning, support those customers in a way that enables them to be successful, which reinforces our own success.

    是的。我想補充的是——我認為我們目前享有的表現,是多年來專注於策略優先事項的累積成果,也是多年來在技術上的投資所帶來的結果;無論是實體配送、機器人流程自動化,或是現在在 AI 上的大型語言模型,這些都轉化為 Kenny 所回顧的毛利槓桿比率。我認為這也反映出團隊在目標上的高度一致與理解:我們每天如何為客戶到位、如何贏得新客戶、如何贏得正在成長的客戶,並以能讓客戶成功的方式支援他們,進而強化我們自身的成功。

  • Operator

    Operator

  • Allen Lutz, Bank of America.

    Allen Lutz,美國銀行。

  • Lisa Gill - Analyst

    Lisa Gill - Analyst

  • Good afternoon, and thanks for taking the questions. I really appreciate the color so far. One for Brian on the capital deployment strategy. As we think about Precision and we think about Option Care, these are new businesses for you relative to what the capital allocation strategy has been around M&A, adding MSO assets and even added Spectrum to PRISM a few days ago. Can you talk about the relative complexity of integration of PMG and Option Care relative to what we've seen over the past couple of years, growing that US oncology business, growing the retina business? Is there a delta there? Would love any perspective.

    下午好,感謝讓我提問。到目前為止提供的補充說明我非常受用。有一題想請教 Brian,關於資本部署策略。當我們思考 Precision 以及 Option Care,對你們而言這些都是相對新的業務;相較之下,你們過去的資本配置策略多圍繞在併購(M&A)、增加 MSO 資產,甚至幾天前也把 Spectrum 加入 PRISM。能否談談 PMG 與 Option Care 的整合相對複雜度,與我們過去幾年看到的(例如)擴大美國腫瘤業務、擴大視網膜業務相比如何?其中是否有差異?希望能聽到任何觀點。

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Yes. It's a really great question. First, I would say, parts of the Precision Medicine Group business are new to us, like the CRO component. They are highly adjacent to businesses that we're already in, and they are highly relevant because of their focus on oncology to our oncology strategy.

    是的,這是一個非常好的問題。首先我會說,Precision Medicine Group 業務的某些部分對我們而言是新的,例如 CRO(委託研究機構)組成。但它們與我們既有業務高度相鄰,也因其聚焦腫瘤領域而與我們的腫瘤策略高度相關。

  • The biopharma services side of that business are natural adjacencies to the businesses that we're already in. And so there's not, per se there, a bunch of integration as much as it is. We now have more solutions that we can put in our bag to offer biopharma manufacturers.

    該業務的生物製藥服務端,與我們已在經營的業務屬於自然相鄰領域。因此嚴格來說,並不需要大量的整合;更多是我們現在有更多解決方案可以納入工具箱,提供給生物製藥製造商。

  • We think we have a great opportunity, I'm not going to say to integrate, but to complement the SCRI capabilities and the PMG capabilities to improve, reimagine, make more efficient and usable and easy the process of getting community-based providers into clinical trials and allowing their patients then to benefit from those therapies.

    我們認為有很好的機會——我不會說是去整合——而是去互補 SCRI 的能力與 PMG 的能力,以改善、重新想像,讓把社區型醫療提供者納入臨床試驗的流程更有效率、更可用、更容易,並讓他們的病患因此受益於這些療法。

  • So we'll be very thoughtful about how we integrate the business. But these are highly complementary businesses with very little overlap but complementarity to the assets that we have. So we're very excited. We think -- I would just remind you on the Option Care side, we are the minority nonoperating partner. So there will be years where this is really under the stewardship of CD&R. We'll bring our knowledge, expertise in specialty and just understanding of supply chain, obviously help that business, but we'll be relying on them to run it day to day.

    因此我們會非常審慎地思考如何整合這項業務。但這些業務彼此高度互補,重疊很少,且能補足我們既有資產。所以我們非常興奮。另外我也提醒各位,在 Option Care 方面,我們是少數且不參與營運的合作夥伴。因此在某些年度,這項業務將主要由 CD&R 來主導管理。我們會帶來在專科領域的知識與專業,以及對供應鏈的理解,當然也會協助該業務,但日常營運將仰賴他們來執行。

  • Kenny Cheung - Executive VP & CFO

    Kenny Cheung - Executive VP & CFO

  • Yes. On Option Care, CD&R is a strong operating partner. We think Option Care is a platform, and it helps having a partner solely focused on strategic investments and growth. And that will be beneficial for us. We will clearly have a voice at the table as well. There'll be proper and appropriate governance. But it really gives an opportunity to grow the business with a strong operating partner that has a lot of experience, while we, as McKesson can also focus on our own 3 -- 2 pillars as well as Oncology & Multispecialty and biopharma services as well. So it's really a win-win proposition.

    是的。就 Option Care 而言,CD&R 是很強的營運夥伴。我們認為 Option Care 是一個平台,而有一位專注於策略性投資與成長的夥伴會很有幫助。這對我們會是有利的。我們也會清楚地在決策桌上有發言權。會有適當且合宜的治理架構。但這確實提供了一個機會:在一位經驗豐富、很強的營運夥伴協助下推動業務成長;同時我們作為 McKesson,也能專注於我們自身的 3——2 大支柱,以及腫瘤與多專科、與生物製藥服務等。所以這真的是雙贏的命題。

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • Last question, please.

    請提最後一個問題。

  • Operator

    Operator

  • Michael Cherny, Leerink Partners.

    Michael Cherny,Leerink Partners。

  • Kevin Caliendo - Analyst

    Kevin Caliendo - Analyst

  • Good afternoon. Thanks for taking the question. This is Dylan Finley on for Mike. Would love to hear you expand a bit on the Option Care deal rationale. Should we think of this as an operating partnership with CD&R, where you could come in and do something on procurement and contracting and drive value? Or is this primarily an equity method investment? And are there currently any supplier arrangements between McKesson and Option Care? And would that be an opportunity for you in future years?

    下午好。感謝讓我提問。我是代替 Mike 的 Dylan Finley。想請你們再多談一些 Option Care 交易的策略理由。我們是否應將其視為與 CD&R 的營運合作夥伴關係,你們可以在採購與合約方面介入並創造價值?還是這主要是一項以權益法認列的投資?另外,目前 McKesson 與 Option Care 之間是否已有任何供應商安排?未來幾年這是否會成為你們的機會?

  • Brain Tyler - CEO & Chairman

    Brain Tyler - CEO & Chairman

  • So first, the Option Care transaction has not closed, so we are still awaiting approval from their shareholders as well as the regulatory agencies. So there are no interfaces ongoing today. We do envision this as a CD&R-run business with the benefits of all the resources and knowledge that McKesson has and can bring to bear around specialty pharmaceuticals, providing care in community-based settings, et cetera.

    首先,Option Care 的交易尚未完成,因此我們仍在等待其股東以及監管機構的核准。所以目前並沒有任何正在進行的介面或合作。我們確實將其設想為由 CD&R 經營的業務,同時也能受益於 McKesson 所擁有並可投入的各項資源與知識,例如專科藥品、在社區型場域提供照護等。

  • And so we really like the future trajectory of community and home-based care. We like the future trajectory of specialty. I think as Kenny said, this allows us to germinate a business outside of the day-to-day operating requirements that have been delivering the results that you've seen us delivering. And so I very much think of this as incubating future growth platforms highly adjacent to our core strategy and supporting our long-term growth algorithm well into the future.

    因此我們非常看好社區與居家照護的未來發展軌跡。我們也看好專科領域的未來走勢。我想如 Kenny 所說,這讓我們能在不受日常營運要求牽制的情況下,培育一項業務;而日常營運要求正是你們看到我們持續交出成果的原因。因此我非常把這視為在我們核心策略高度相鄰的領域中,孵化未來成長平台,並在未來很長一段時間內良好支撐我們的長期成長算法。

  • Perfect. Great questions. Appreciate everybody taking time to join us. There's a lot going on in the world today that we're all aware of. Look, I'm very pleased with the results that McKesson delivered in our fiscal second quarter. They were very strong. Our strategy is working. Our execution is strong. I'm confident in our ability to continue to deliver long-term sustainable growth for our shareholders.

    很好。問題都很棒。感謝各位撥冗參與。今天世界上發生很多事情,我們都很清楚。我對 McKesson 在本財年第二季所交出的成果非常滿意。表現非常強勁。我們的策略正在奏效。我們的執行力很強。我對我們持續為股東帶來長期、可持續成長的能力充滿信心。

  • This does not happen without Team McKesson. So I want to thank them for their continued dedication to advancing our mission. They're unwavering in their commitment to our customers and to our customers' patients and to each other. And they are the foundation for all of the success we will continue to have. So thanks, everybody. I hope you have a great night.

    沒有 McKesson 團隊,這一切不可能發生。因此我要感謝他們持續投入,推進我們的使命。他們對客戶、對客戶的病患,以及彼此之間的承諾始終如一。他們是我們未來持續成功的基石。所以謝謝大家。祝各位今晚愉快。

  • Operator

    Operator

  • Thank you for joining today's conference call. You may now disconnect and have a great day.

    感謝您參加今天的電話會議。您現在可以掛線,祝您有美好的一天。